Eptinezumab: Promising Migraine Relief for Treatment-Resistant Cases

Research Summary

A recent study published in the Journal of Headache and Pain presents the first UK real-world analysis of intravenous eptinezumab for migraine management. This prospective open-label study followed 119 migraine patients, who had previously failed an average of 10.2 preventive treatments, over six months. After the first infusion of eptinezumab, 51% of patients experienced at least a 30% reduction in monthly migraine days, with an average decrease of 5.4 days. By six months, 63% saw similar improvements, with an average reduction of 6.3 days. Eptinezumab was more effective in those naive to other anti-CGRP mAbs. Side effects were minimal, leading to its consideration as a potentially effective treatment option for those unresponsive to previous therapies.

Study Details

📄 Title: A prospective real-world analysis of intravenous eptinezumab in migraine management: the first UK experience.

👥 Research Team: Andreou AP et al.

📚 Published In: J Headache Pain

📅 Publication Date: 2025 Oct 30

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.